The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis

Ithamar Heber Brinkman, Mart A F J van de Laar, Tim L. Jansen, E.N. van Roon

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Dutch
Pages (from-to)	715-726
Journal	Expert opinion on drug safety
Volume	10
Issue number	5
DOIs	https://doi.org/10.1517/14740338.2011.562188
Publication status	Published - 2011

Keywords

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{5653e85253ff46f9be9b568f7ad8cd4a,

title = "The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis",

keywords = "METIS-282236",

author = "Brinkman, {Ithamar Heber} and {van de Laar}, {Mart A F J} and Jansen, {Tim L.} and {van Roon}, E.N.",

year = "2011",

doi = "10.1517/14740338.2011.562188",

language = "Dutch",

volume = "10",

pages = "715--726",

journal = "Expert opinion on drug safety",

issn = "1474-0338",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis

AU - Brinkman, Ithamar Heber

AU - van de Laar, Mart A F J

AU - Jansen, Tim L.

AU - van Roon, E.N.

PY - 2011

Y1 - 2011

KW - METIS-282236

U2 - 10.1517/14740338.2011.562188

DO - 10.1517/14740338.2011.562188

M3 - Article

SN - 1474-0338

VL - 10

SP - 715

EP - 726

JO - Expert opinion on drug safety

JF - Expert opinion on drug safety

IS - 5

ER -